
Hexagon Nutrition Limited
HEXAGONListedMainboard IPO · NSE, BSE
Price Band
₹42 – ₹45
Lot Size
333 shares
Issue Size
₹139 Cr
GMP (Grey Market Premium)
🔒 Login to view
Hexagon Nutrition Limited is a research-oriented nutrition company engaged in the development, manufacturing, and marketing of a wide range of nutrition products. The company operates across the nutrition value chain, offering micronutrient premixes, therapeutic and clinical nutrition products, and solutions for food fortification and malnutrition. It provides customised vitamin and mineral premixes to domestic and international fast-moving consumer goods companies and also supplies micronutrient powders for public health programmes. Its product portfolio addresses various nutritional needs, including clinical nutrition and preventive healthcare. The company follows an integrated business model, with capabilities spanning research and development, production, and distribution, and focuses on quality-driven offerings. Revenue is primarily generated through the sale of these nutrition products across different customer segments, including institutional and commercial clients. Discuss on Trading Q&A
| IPO Open Date | 5 Jun 2026 |
| IPO Close Date | 9 Jun 2026 |
| Basis of Allotment | 10 Jun 2026 |
| Refunds Initiation | 11 Jun 2026 |
| Listing Date | 12 Jun 2026 |
| Face Value | — |
| Fresh Issue | — |
| Offer for Sale | — |
| Minimum Investment (Retail) | ₹14,985 |
| Registrar | — |
| Lead Managers | — |
| Issue open date | 5 Jun 2026 |
| Issue close date | 9 Jun 2026 |
| UPI mandate deadline | 9 Jun 2026 |
| Allotment finalization | 10 Jun 2026 |
| Refund initiation | 11 Jun 2026 |
| Share credit | 11 Jun 2026 |
| Listing date | 12 Jun 2026 |
| Mandate end date | 24 Jun 2026 |
| Lock-in end date for anchor investors (50%) | 9 Jul 2026 |
| Lock-in end date for anchor investors (remaining) | 7 Sept 2026 |
- Integrated nutrition company with capabilities from R&D to manufacturing and marketing.
- Diverse product portfolio covering premixes, clinical, and therapeutic nutrition.
- Strong presence in micronutrient premixes for FMCG companies.
- Supplier to global public health programmes for micronutrient powders.
- Focus on research-driven and quality-oriented product development.
- Heavy dependence on the premix formulation segment for revenue.
- High revenue concentration from a limited number of customers.
- Exposure to raw material price volatility due to a lack of long-term contracts.
- Risk of product quality issues leading to liability and reputational damage.
- Dependence on successful R&D and new product commercialisation.
